Life Technologies Corporation

Life Technologies Corporation, a wholly owned subsidiary of Thermo Fisher Scientific Inc. headquartered in Grand Island, New York, supplies specialized biomedical research instruments, reagents, consumables, and laboratory equipment to federal agencies as a prime contractor across more than 100 customer organizations. The company operates exclusively in full-and-open federal procurement with no set-aside certifications, competing on proprietary technology and specialized scientific capabilities rather than small-business designations. Life Technologies' federal footprint spans nearly three decades, with 2,996 total awards recorded across recent and historical federal sources; however, annual award volume has declined materially — from 64 awards in 2022 to just 7 awarded through May 2026 — suggesting a shift in buying patterns or contract consolidation within the parent Thermo Fisher entity.

Life Technologies' capability portfolio centers on genetic analysis instruments (Applied Biosystems 3500XL and 7500 Real-Time PCR systems, QuantStudio platforms, Ion Torrent sequencers), multiplexed immunoassay systems (Luminex xMAP INTELLIFLEX, ProcartaPlex kits), flow cytometry equipment (Attune CytPix), and proprietary molecular diagnostic reagents (TaqMan master mixes, BigDye Terminator cycle sequencing kits, HIV genotyping kits, PCR test kits). Representative recent work includes a $128,790 delivery to the Bureau of Medicine and Surgery for laboratory reagents supporting molecular diagnosis of influenza and other pathogens at Naval Medical Research Unit South in Lima, Peru; a $111,990.68 preventive maintenance order from VA Veterans Integrated Service Network 16 for an Ion S5 Plus sequencer running through 2030; and a $249,481.80 EPA procurement for two Luminex xMAP INTELLIFLEX instruments deployed across research facilities in North Carolina, Ohio, and California. The $72,295 National Institute of Diabetes and Digestive and Kidney Diseases award for a Luminex xMAP INTELLIFLEX System exemplifies the vendor's role in replacing legacy equipment and enabling precision medicine research.

Customer concentration clusters around civilian health and research agencies. The top five customers by potential value account for 52 percent of combined potential value: the Department of Health and Human Services Office of the Assistant Secretary for Administration ($15.4 million across 29 awards), CDC Pittsburgh ($8.7 million across 158 awards), the Navy Bureau of Medicine and Surgery ($7.8 million across 94 awards), the FBI Headquarters Division ($4.1 million across 27 awards), and CDC Office of Acquisition Services ($3.2 million across 120 awards). The volume and dollar rankings diverge notably — CDC Pittsburgh dominates by award count but ranks second by dollars, while HHS ASA concentrates fewer, larger-value awards. This suggests Life Technologies supplies both high-volume consumables and standalone instrument procurements. Across the portfolio, purchases cluster in analytical laboratory instrument manufacturing (470 awards), biological product manufacturing (325 awards), and in-vitro diagnostic substance manufacturing (269 awards).

Life Technologies holds limited active indefinite delivery vehicles. The Blanket Purchase Agreement EPBPA12W0013 carries 17 task orders worth $281 thousand combined potential value; an Indefinite Delivery Contract 75N91018D00037 carries 7 task orders worth $247 thousand; and Federal Supply Schedule V797P5253N carries 7 task orders of unspecified value. A single-award blanket purchase agreement with VA Veterans Integrated Service Network 15 for pathology and laboratory sequencing reagents ran through June 30, 2024, at $1.45 million ceiling. These vehicles are modest in scale relative to the prime footprint, indicating most federal work flows through individual purchase orders rather than standing vehicles.

Activity has contracted sharply in recent years. Awards per year declined from 64 in 2022 to 26 in 2025 and 7 through May 2026 — a 70 percent drop over four years. Thirteen awards (combined potential value $908 thousand) reach ultimate completion within the next twenty-four months and face recompete exposure. This trajectory suggests either consolidation within Thermo Fisher's broader portfolio, shifts in federal buying toward parent-company contracts, or narrower customer demand for Life Technologies' standalone offerings.

Life Technologies operates almost exclusively as a prime contractor; only 10 of 2,996 awards (0.3 percent) are sub-awards. The sub portfolio includes service agreements for ABI 7500 Fast qPCR machines and Life Tech instrument maintenance delivered to Battelle National Biodefense Institute (operating the National Biodefense Analysis and Countermeasures Center under DHS contract), and consumable supplies provided to the Ohio Attorney General's office under a grant sub-award. This minimal sub presence reflects Life Technologies' positioning as a direct vendor to federal laboratories rather than as a teaming partner on systems integrations or larger program management contracts.

Life Technologies competes in commodity-like federal procurement channels — simplified acquisition procedures and firm fixed-price purchase orders dominate the award record — with sole-source justifications grounded in proprietary technology, compatibility with existing federal equipment platforms, and the specialized nature of reagents and consumables. The company supplies equipment maintenance and consumables where federal agencies have already standardized on Thermo Fisher platforms, creating switching costs that anchor sole-source or competitive set-asides. This narrow capability positioning and declining award velocity position Life Technologies primarily as a reagent and maintenance supplier to federal life sciences organizations rather than as a strategic supplier or prime on major multi-agency programs.